Axial Spondyloarthritis, Psoriatic Arthritis
Conditions
Keywords
Axial spondyloarthritis;, Psoriatic Arthritis;, electronic health records;, natural language processing;, artificial intelligence
Brief summary
This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.
Interventions
DRUGsecukinumab
all patients who received secukinumab
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥ 18 years. * Diagnosed with axSpA or PsA. * Had received or are receiving bDMARD, independently of the line of treatment, from January 2018 to data collection. * Had at least 3 months follow up from first bDMARD administration. * Patients with EHRs.
Exclusion criteria
• Receiving bDMARD within a clinical trial from January 2018 to data collection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients achieving disease control status at 6 months (±3 months) of secukinumab treatment | month 6 | Disease control was defined as: For Axial Spondyloarthritis (axSpA) population: Bath Ankylosing Spondylitis Functional Index (BASDAI) score \< 4. If BASDAI was not available, Ankylosing Spondylitis Disease Activity Score (ASDAS) \< 2.1 was used. For Psoriatic Arthritis (PsA) population: Disease Activity in PSoriatic Arthritis (DAPSA) score \< 14. If DAPSA was not available, Disease activity score 28 (DAS-28) \< 3.2 was used. |
Countries
Spain
Outcome results
None listed